

Adipokines and cytokines in non-alcoholic fatty liver

Alimentary Pharmacology and Therapeutics

27, 412-421

DOI: [10.1111/j.1365-2036.2007.03586.x](https://doi.org/10.1111/j.1365-2036.2007.03586.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Adipocytokines and liver disease. <i>Journal of Gastroenterology</i> , 2008, 43, 811-822.	2.3	148
2	Resveratrol inhibits nonalcoholic fatty liver disease in rats. <i>BMC Gastroenterology</i> , 2008, 8, 40.	0.8	180
3	Adipokines and cytokines in nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 266-267.	1.9	12
4	Adipokines and cytokines in nonalcoholic fatty liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 267-268.	1.9	3
5	Rubratoxin B induces interleukin-6 secretion in mouse white adipose tissues and 3T3-L1 adipocytes. <i>Toxicology Letters</i> , 2008, 182, 79-83.	0.4	3
6	Insulin resistance, inflammation, and non-alcoholic fatty liver disease. <i>Trends in Endocrinology and Metabolism</i> , 2008, 19, 371-379.	3.1	402
7	Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. <i>Pharmacological Reviews</i> , 2008, 60, 311-357.	7.1	346
8	Noninvasive diagnosis of nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2009, 8, S25-S33.	0.6	40
9	Nonalcoholic Fatty Liver Disease as a Contributor to Hypercoagulation and Thrombophilia in the Metabolic Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 277-287.	1.5	123
10	Adiponectin-stimulated CXCL8 release in primary human hepatocytes is regulated by ERK1/ERK2, p38 MAPK, NF- κ B, and STAT3 signaling pathways. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, G611-G618.	1.6	62
11	Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy. <i>Mediators of Inflammation</i> , 2009, 2009, 1-8.	1.4	105
12	The role of resistin as a regulator of inflammation: Implications for various human pathologies. <i>Clinical Immunology</i> , 2009, 133, 157-170.	1.4	345
13	Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. <i>Hepatology</i> , 2009, 49, 80-86.	3.6	399
14	Adipokines in liver diseases. <i>Hepatology</i> , 2009, 50, 957-969.	3.6	410
15	Adipokine Serum Levels Are Related to Liver Histology in Severely Obese Patients Undergoing Bariatric Surgery. <i>Obesity Surgery</i> , 2009, 19, 1313-1323.	1.1	43
16	The value of serum adipokine measurement in nonalcoholic fatty liver disease. <i>Liver International</i> , 2009, 29, 1291-1293.	1.9	5
17	Expression of Cytokine Signaling Genes in Morbidly Obese Patients with Non-Alcoholic Steatohepatitis and Hepatic Fibrosis. <i>Obesity Surgery</i> , 2009, 19, 617-624.	1.1	44
18	Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 695-700.	1.8	32

#	ARTICLE	IF	CITATIONS
19	Suppression of hepatic fat accumulation by highly purified eicosapentaenoic acid prevents the progression of d-galactosamine-induced hepatitis in mice fed with a high-fat/high-sucrose diet. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 281-288.	1.2	13
20	Kupffer cells in non-alcoholic fatty liver disease: The emerging view. <i>Journal of Hepatology</i> , 2009, 51, 212-223.	1.8	402
21	Visceral Obesity and Hypoadiponectinemia are Significant Determinants of Hepatic Dysfunction. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 995-1000.	1.1	22
22	Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2009, 53, 201-212.	1.3	72
23	Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 662-666.	0.8	40
24	Endotoxin and Plasminogen Activator Inhibitor-1 Serum Levels Associated With Nonalcoholic Steatohepatitis in Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2010, 50, 645-649.	0.9	126
25	Nonlinear Distribution of Adiponectin in Patients With Nonalcoholic Fatty Liver Disease Limits Its Use in Linear Regression Analysis. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 229-230.	1.1	19
26	Significance of serum adiponectin levels in patients with chronic liver disease. <i>Clinical Science</i> , 2010, 119, 431-436.	1.8	47
27	Fatty liver disease in children: eat now pay later. <i>Hepatology International</i> , 2010, 4, 375-385.	1.9	33
28	Hypoadiponectinemia and its Association with Liver Fibrosis in Morbidly Obese Patients. <i>Obesity Surgery</i> , 2010, 20, 1400-1407.	1.1	24
29	Pro- and Anti-inflammatory Cytokines in Steatosis and Steatohepatitis. <i>Obesity Surgery</i> , 2010, 20, 906-912.	1.1	28
30	Negative correlation between neuropeptide Y/agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 613-619.	1.5	24
31	Visfatin, glucose metabolism and vascular disease: a review of evidence. <i>Diabetology and Metabolic Syndrome</i> , 2010, 2, 21.	1.2	117
32	Clinical Review of Nonalcoholic Steatohepatitis in Liver Surgery and Transplantation. <i>Journal of the American College of Surgeons</i> , 2010, 210, 515-526.	0.2	34
33	Xanthohumol, a chalcon derived from hops, inhibits hepatic inflammation and fibrosis. <i>Molecular Nutrition and Food Research</i> , 2010, 54, S205-13.	1.5	82
34	Amino acids stimulate Akt phosphorylation, and reduce IL-8 production and NF- κ B activity in HepG2 liver cells. <i>Molecular Nutrition and Food Research</i> , 2010, 54, 1568-1573.	1.5	31
35	Nonalcoholic fatty liver disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 695-708.	1.0	158
36	Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation <i>in vitro</i> and <i>in vivo</i> in a rat model. <i>Liver International</i> , 2010, 30, 365-375.	1.9	44

#	ARTICLE	IF	CITATIONS
37	Visfatin serum levels in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2010, 17, 254-260.	1.0	26
38	Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease: a cross-sectional study in Japanese men and women. <i>European Journal of Clinical Nutrition</i> , 2010, 64, 1179-1185.	1.3	48
39	Nonalcoholic fatty liver disease: a challenge for pediatricians. <i>International Journal of Obesity</i> , 2010, 34, 1451-1467.	1.6	55
40	Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. <i>Laboratory Investigation</i> , 2010, 90, 1169-1178.	1.7	94
41	The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 365-383.	2.2	220
42	Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 562-567.	1.4	114
43	A fresh look at NASH pathogenesis. Part 1: The metabolic movers. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 672-690.	1.4	153
44	Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2010, 9, 266-270.	0.6	33
45	Intracellular Nicotinamide Phosphoribosyltransferase Protects against Hepatocyte Apoptosis and Is Down-Regulated in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3039-3047.	1.8	89
46	Serum Levels of CK18 M30 and Leptin Are Useful Predictors of Steatohepatitis and Fibrosis in Paediatric NAFLD. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2010, 51, 500-506.	0.9	96
47	Nonalcoholic steatohepatitis: risk factors and diagnosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 623-635.	1.4	45
48	Indirect markers of non-alcoholic fatty liver disease: Another piece of the puzzle?. <i>Digestive and Liver Disease</i> , 2010, 42, 846-847.	0.4	1
49	Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2010, 5, 145-171.	9.6	710
50	Selenium supplementation attenuates procollagen-1 and interleukin-8 production in fat-loaded human C3A hepatoblastoma cells treated with TGF β 1. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2010, 1800, 611-618.	1.1	18
51	Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 376-381.	1.0	128
52	Association of increased Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 21, 245-53.	1.1	48
53	Heme oxygenase-1 prevents non-alcoholic steatohepatitis through suppressing hepatocyte apoptosis in mice. <i>Lipids in Health and Disease</i> , 2010, 9, 124.	1.2	34
54	Suboptimal maternal nutrition, during early fetal liver development, promotes lipid accumulation in the liver of obese offspring. <i>Reproduction</i> , 2011, 141, 119-126.	1.1	50

#	ARTICLE	IF	CITATIONS
55	Serum levels of omentin, chemerin and adiponin in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 91-97.	0.6	107
56	Inflammation in nonalcoholic steatohepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 189-200.	1.4	72
57	Non-alcoholic fatty liver disease. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2011, 48, 97-113.	2.7	253
58	Drug metabolism alterations in nonalcoholic fatty liver disease. <i>Drug Metabolism Reviews</i> , 2011, 43, 317-334.	1.5	136
59	Sphingolipids and Hepatic Steatosis. <i>Advances in Experimental Medicine and Biology</i> , 2011, 721, 87-97.	0.8	40
60	Regular exercise prevents high-sucrose diet-induced fatty liver via improvement of hepatic lipid metabolism. <i>Biochemical and Biophysical Research Communications</i> , 2011, 413, 330-335.	1.0	24
61	Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 587-593.	1.2	90
62	Some inflammatory cytokine levels, iron metabolism and oxidant stress markers in subjects with nonalcoholic steatohepatitis. <i>Clinical Biochemistry</i> , 2011, 44, 1375-1379.	0.8	48
63	Potential Role of Leptin, Adiponectin and Three Novel Adipokines—Visfatin, Chemerin and Vaspin—in Chronic Hepatitis. <i>Molecular Medicine</i> , 2011, 17, 1397-1410.	1.9	82
64	Nonalcoholic Fatty Liver Disease in Children. <i>Korean Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 14, 209.	0.2	4
65	Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. <i>Archives of Medical Science</i> , 2011, 5, 796-805.	0.4	72
66	Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 530-535.	1.4	13
67	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 153-162.	1.4	93
68	Melanin and melanogenesis in adipose tissue: possible mechanisms for abating oxidative stress and inflammation?. <i>Obesity Reviews</i> , 2011, 12, e21-31.	3.1	49
69	Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 525-540.	1.9	254
70	Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 801-814.	1.9	122
71	Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. <i>Liver International</i> , 2011, 31, 461-473.	1.9	41
72	Psoriasis and non-alcoholic fatty liver disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 383-391.	1.3	55

#	ARTICLE	IF	CITATIONS
73	Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. <i>International Journal of Obesity</i> , 2011, 35, 270-278.	1.6	45
74	Blockade of IL-6 signaling exacerbates liver injury and suppresses antiapoptotic gene expression in methionine choline-deficient diet-Fed db/db mice. <i>Laboratory Investigation</i> , 2011, 91, 609-618.	1.7	52
75	Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 313-326.	1.5	272
76	Plasma adiponectin is an independent indicator of liver fat accumulation. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1515-1520.	1.5	20
77	Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1524-1534.	1.1	165
78	Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects. <i>Journal of Nutritional Biochemistry</i> , 2011, 22, 289-292.	1.9	35
79	Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies. <i>Toxicology</i> , 2011, 279, 10-18.	2.0	51
80	Adipokines and Redox Signaling: Impact on Fatty Liver Disease. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 461-483.	2.5	52
81	Association of Serum Adipocytokines with Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C. <i>Digestion</i> , 2011, 83, 32-40.	1.2	20
82	Obesity Affects the Liver – The Link between Adipocytes and Hepatocytes. <i>Digestion</i> , 2011, 83, 124-133.	1.2	179
83	Possible Role of Visfatin in Hepatoma Progression and the Effects of Branched-Chain Amino Acids on Visfatin-Induced Proliferation in Human Hepatoma Cells. <i>Cancer Prevention Research</i> , 2011, 4, 2092-2100.	0.7	54
84	Molecular Mechanisms of Liver Injury and Hepatocarcinogenesis: Focusing on the Role of Stress-Activated MAPK. <i>Pathology Research International</i> , 2012, 2012, 1-14.	1.4	64
85	Focus on Therapeutic Strategies of Nonalcoholic Fatty Liver Disease. <i>International Journal of Hepatology</i> , 2012, 2012, 1-9.	0.4	23
86	The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 262-269.	0.8	30
87	How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1166-1172.	0.8	75
88	Insulin Resistance Predicts Steatosis and Fibrosis in Morbidly Obese Patients Undergoing Bariatric Surgery. <i>Journal of Investigative Medicine</i> , 2012, 60, 1005-1008.	0.7	5
89	Oiling vascular growth: adipokines can induce (pathological) angiogenesis by using the VEGF/VEGFR system: EXPERTS' PERSPECTIVE. <i>Cardiovascular Research</i> , 2012, 96, 220-222.	1.8	1
90	Comment on: Diet-induced obesity associated with steatosis, oxidative stress and inflammation in liver. <i>Surgery for Obesity and Related Diseases</i> , 2012, 8, 81-83.	1.0	0

#	ARTICLE	IF	CITATIONS
91	Lower plasma NAMPT/visfatin levels are associated with impaired hepatic mitochondrial function in non-diabetic obese women: A potential link between obesity and non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, e1-e2.	1.1	7
92	Low concentrations of bisphenol A induce lipid accumulation mediated by the production of reactive oxygen species in the mitochondria of HepG2 cells. <i>Toxicology in Vitro</i> , 2012, 26, 709-717.	1.1	159
93	The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. <i>Liver International</i> , 2012, 32, 701-711.	1.9	159
94	Obesity, inflammation, and liver cancer. <i>Journal of Hepatology</i> , 2012, 56, 704-713.	1.8	428
95	Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. <i>Journal of Hepatology</i> , 2012, 56, 663-670.	1.8	87
96	Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. <i>Cytokine</i> , 2012, 59, 442-449.	1.4	100
97	Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- α -lowering property. <i>Digestive and Liver Disease</i> , 2012, 44, 492-496.	0.4	50
98	Role of cytokines and chemokines in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2012, 18, 727.	1.4	280
99	TNF- α messenger ribonucleic acid (mRNA) in patients with nonalcoholic steatohepatitis. <i>European Cytokine Network</i> , 2012, 23, 107-111.	1.1	21
101	Visfatin Levels in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Laboratory Analysis</i> , 2012, 26, 115-119.	0.9	20
102	A role for sphingolipids in the pathophysiology of obesity-induced inflammation. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 2135-2146.	2.4	59
103	Inflammation and fibrogenesis in steatohepatitis. <i>Journal of Gastroenterology</i> , 2012, 47, 215-225.	2.3	123
104	Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: A retrospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 91-95.	1.4	74
105	Caffeine is protective in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 76-82.	1.9	123
106	Hop bitter acids exhibit anti-fibrogenic effects on hepatic stellate cells in vitro. <i>Experimental and Molecular Pathology</i> , 2012, 92, 222-228.	0.9	22
107	The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: A study from South India. <i>Australasian Journal of Dermatology</i> , 2012, 53, 190-197.	0.4	71
108	Obesity, adipokines and hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2013, 133, 1776-1783.	2.3	66
109	Maternal high-fat diet is associated with altered pancreatic remodelling in mice offspring. <i>European Journal of Nutrition</i> , 2013, 52, 759-769.	1.8	30

#	ARTICLE	IF	CITATIONS
110	Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. <i>Clinical Biochemistry</i> , 2013, 46, 202-208.	0.8	59
111	Angiogenesis: a phenomenon which aggravates chronic liver disease progression. <i>Hepatology International</i> , 2013, 7, 4-12.	1.9	28
112	Markers in Nonalcoholic Steatohepatitis. <i>Advances in Clinical Chemistry</i> , 2013, 61, 67-125.	1.8	16
113	Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. <i>Obesity</i> , 2013, 21, 583-590.	1.5	57
114	Dietary supplementation with methyl donors reduces fatty liver and modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet. <i>Genes and Nutrition</i> , 2013, 8, 105-113.	1.2	156
115	Manipulating molecular switches in brown adipocytes and their precursors: A therapeutic potential. <i>Progress in Lipid Research</i> , 2013, 52, 51-61.	5.3	34
116	Sleep duration and quality in relation to non-alcoholic fatty liver disease in middle-aged workers and their spouses. <i>Journal of Hepatology</i> , 2013, 59, 351-357.	1.8	131
117	Adiponectin and resistin protect steatotic livers undergoing transplantation. <i>Journal of Hepatology</i> , 2013, 59, 1208-1214.	1.8	29
118	An integrated view of liver injury and disease progression in nonalcoholic steatohepatitis. <i>Hepatology International</i> , 2013, 7, 800-805.	1.9	3
119	Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. <i>Journal of Hepatology</i> , 2013, 58, 1007-1019.	1.8	332
120	Association of Serum Adiponectin, Leptin, and Resistin Concentrations with the Severity of Liver Dysfunction and the Disease Complications in Alcoholic Liver Disease. <i>Mediators of Inflammation</i> , 2013, 2013, 1-12.	1.4	20
121	Sphingolipid Metabolism and Obesity-Induced Inflammation. <i>Frontiers in Endocrinology</i> , 2013, 4, 67.	1.5	49
122	Expression of Inflammation-Related Genes Is Altered in Gastric Tissue of Patients with Advanced Stages of NAFLD. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	1.4	5
123	Choline's role in maintaining liver function. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2013, 16, 339-345.	1.3	92
124	Acute Steatohepatitis, Due to Extreme Metabolic Dysregulation, as the First Presentation of Non-Alcoholic Fatty Liver Disease. <i>Clinics and Practice</i> , 2013, 3, 43-45.	0.6	1
125	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <i>Journal of Clinical Pathology</i> , 2013, 66, 1033-1045.	1.0	70
126	What does irritable bowel syndrome share with non-alcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2013, 19, 5402.	1.4	29
127	Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example. <i>PLoS ONE</i> , 2013, 8, e56009.	1.1	15

#	ARTICLE	IF	CITATIONS
128	Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. <i>Annals of Hepatology</i> , 2013, 12, 749-757.	0.6	29
129	Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2013, 12, 380-387.	0.6	83
130	Molecular pathways in non-alcoholic fatty liver disease. <i>Clinical and Experimental Gastroenterology</i> , 2014, 7, 221.	1.0	279
131	Non-Alcoholic Fatty Liver Disease in Children: Focus on Nutritional Interventions. <i>Nutrients</i> , 2014, 6, 4691-4705.	1.7	31
132	Diagnosis of Non-alcoholic Fatty Liver Disease. <i>Journal of Korean Diabetes</i> , 2014, 15, 82.	0.1	0
133	Non-alcoholic fatty liver disease and thyroid dysfunction: A systematic review. <i>World Journal of Gastroenterology</i> , 2014, 20, 8102.	1.4	113
134	Serum visfatin in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2014, 13, 150-151.	0.6	3
135	Steatosis and Steatohepatitis: Complex Disorders. <i>International Journal of Molecular Sciences</i> , 2014, 15, 9924-9944.	1.8	31
136	Hypoadiponectinaemia in nonalcoholic fatty liver disease obese women is associated with infrequent intake of dietary sucrose and fatty foods. <i>Journal of Human Nutrition and Dietetics</i> , 2014, 27, 301-312.	1.3	8
137	Oral Coenzyme Q10 Supplementation in Patients with Nonalcoholic Fatty Liver Disease: Effects on Serum Vaspin, Chemerin, Pentraxin 3, Insulin Resistance and Oxidative Stress. <i>Archives of Medical Research</i> , 2014, 45, 589-595.	1.5	83
138	Multiple Factors Predict Physical Performance in People with Chronic Liver Disease. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2014, 93, 470-476.	0.7	20
139	Role of Innate Immune Response in Non-Alcoholic Fatty Liver Disease: Metabolic Complications and Therapeutic Tools. <i>Frontiers in Immunology</i> , 2014, 5, 177.	2.2	116
140	4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine—recommendations for facing obesity, fatty liver and fibrosis epidemics. <i>EPMA Journal</i> , 2014, 5, 21.	3.3	29
141	Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <i>Postgraduate Medical Journal</i> , 2014, 90, 254-266.	0.9	12
142	Adipokines in Nonalcoholic Fatty Liver Disease. , 2014, , 249-283.		2
143	Non-viral causes of liver cancer: Does obesity led inflammation play a role?. <i>Cancer Letters</i> , 2014, 345, 223-229.	3.2	62
144	Resistin and visfatin in steatotic and non-steatotic livers in the setting of partial hepatectomy under ischemia-reperfusion. <i>Journal of Hepatology</i> , 2014, 60, 87-95.	1.8	18
145	Evaluation of Clinical and Inflammatory Markers of Nonalcoholic Fatty Liver Disease in Postmenopausal Women with Metabolic Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2014, 12, 330-338.	0.5	9

#	ARTICLE	IF	CITATIONS
146	Chronic stress induces steatohepatitis while decreases visceral fat mass in mice. <i>BMC Gastroenterology</i> , 2014, 14, 106.	0.8	31
147	Nonalcoholic Fatty Liver Disease Increases Risk for Gastroesophageal Reflux Symptoms. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1939-1945.	1.1	18
148	The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2014, 14, 39.	0.8	52
149	Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin-18 fragments. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 254-269.	1.9	320
150	Nonalcoholic fatty liver disease and metabolic syndrome in postmenopausal women. <i>Gynecological Endocrinology</i> , 2014, 30, 325-329.	0.7	15
151	Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. <i>Clinical and Experimental Medicine</i> , 2014, 14, 121-131.	1.9	53
152	Clinical approaches to non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 1712.	1.4	111
153	Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 18070.	1.4	260
154	Protective effects and mechanisms of total alkaloids of <i>Rubus alceaefolius</i> Poir on non-alcoholic fatty liver disease in rats. <i>Molecular Medicine Reports</i> , 2014, 10, 1758-1764.	1.1	7
155	Changes in concentration of visfatin during four weeks of inpatient treatment of alcohol dependent males. <i>Alkoholizm I Narkomania</i> , 2015, 28, 173-181.	0.3	3
156	The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control study. <i>Diabetology and Metabolic Syndrome</i> , 2015, 7, 108.	1.2	24
157	Liver and oxidative stress. <i>Acta Hepatologica Japonica</i> , 2015, 56, 313-323.	0.0	2
158	Non-alcoholic fatty liver disease and psoriasis: So far, so near. <i>World Journal of Hepatology</i> , 2015, 7, 315.	0.8	51
159	The hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels. <i>Frontiers in Physiology</i> , 2015, 6, 140.	1.3	43
160	Antiresistin RNA Oligonucleotide Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease in Mice through Attenuating Proinflammatory Cytokines. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	8
161	LUBAC Formation Is Impaired in the Livers of Mice with MCD-Dependent Nonalcoholic Steatohepatitis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	1.4	20
162	Osthole inhibits inflammatory cytokine release through PPAR α -mediated mechanisms in LPS-stimulated 3T3-L1 adipocytes. <i>Immunopharmacology and Immunotoxicology</i> , 2015, 37, 185-192.	1.1	18
163	PAEDIATRIC NON ALCOHOLIC FATTY LIVER DISEASE: AN EMERGING THREAT. <i>Paediatrics Today</i> , 2015, 11, 1-9.	0.1	6

#	ARTICLE	IF	CITATIONS
164	Misoprostol modulates cytokine expression through a cAMP pathway: Potential therapeutic implication for liver disease. <i>Clinical Immunology</i> , 2015, 161, 291-299.	1.4	12
165	Non-alcoholic fatty liver disease associated with increased arterial stiffness in subjects with normal glucose tolerance, but not pre-diabetes and diabetes. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 359-365.	0.9	7
166	<i>Lactobacillus rhamnosus</i> LA68 and <i>Lactobacillus plantarum</i> WCFS1 differently influence metabolic and immunological parameters in high fat diet-induced hypercholesterolemia and hepatic steatosis. <i>Food and Function</i> , 2015, 6, 558-565.	2.1	43
167	Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. <i>Digestive and Liver Disease</i> , 2015, 47, 226-232.	0.4	251
168	Diagnostic performances of serum liver enzymes and cytokines in non-alcoholic fatty liver disease. <i>Journal of Clinical and Experimental Investigations</i> , 2015, 6, .	0.1	0
169	The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. <i>Journal of Clinical and Experimental Hepatology</i> , 2015, 5, 147-158.	0.4	114
170	Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial. <i>Pharmacological Research</i> , 2015, 99, 74-81.	3.1	173
171	Oxidative Stress in Obesity: A Critical Component in Human Diseases. <i>International Journal of Molecular Sciences</i> , 2015, 16, 378-400.	1.8	654
172	Protective effect of oroxylin A against lipopolysaccharide and/or D-galactosamine-induced acute liver injury in mice. <i>Journal of Surgical Research</i> , 2015, 195, 522-528.	0.8	30
173	Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e95.	1.3	16
174	Adipokines, Vascular Wall, and Cardiovascular Disease. <i>Angiology</i> , 2015, 66, 8-24.	0.8	23
175	Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD. <i>Liver International</i> , 2015, 35, 1367-1372.	1.9	22
176	Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high-fat diet fed mice. <i>Liver International</i> , 2015, 35, 550-561.	1.9	38
177	Resistin: Insulin resistance to malignancy. <i>Clinica Chimica Acta</i> , 2015, 438, 46-54.	0.5	109
178	Metabolic Inflammation-Differential Modulation by Dietary Constituents. <i>Nutrients</i> , 2016, 8, 247.	1.7	77
179	High Protein/Fish Oil Diet Prevents Hepatic Steatosis in NONcNZO10 Mice; Association with Diet/Genetics-regulated Micro-RNAs. <i>Journal of Diabetes & Metabolism</i> , 2016, 7, .	0.2	8
180	The Correlation Between Serum Adipokines and Liver Cell Damage in Non-Alcoholic Fatty Liver Disease. <i>Hepatitis Monthly</i> , 2016, 16, e37412.	0.1	15
181	Histopathologic Evaluation of Nonalcoholic Fatty Liver Disease in Hypothyroidism-Induced Rats. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-7.	0.6	9

#	ARTICLE	IF	CITATIONS
182	Effect of curcumin on visfatin and zinc- α 2-glycoprotein in a rat model of non-alcoholic fatty liver disease. <i>Acta Cirurgica Brasileira</i> , 2016, 31, 706-713.	0.3	16
183	Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells. <i>Frontiers in Endocrinology</i> , 2016, 7, 67.	1.5	75
184	Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1379.	1.8	48
185	Short sleep duration and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1802-1807.	1.4	40
186	Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells. <i>Cellular Physiology and Biochemistry</i> , 2016, 40, 453-464.	1.1	55
187	Nonalcoholic Fatty Liver Disease: Prognosis and Progression of Disease. <i>Current Hepatology Reports</i> , 2016, 15, 117-124.	0.4	1
188	TNF and IL-18 cytokines may regulate liver fat storage under homeostasis conditions. <i>Applied Physiology, Nutrition and Metabolism</i> , 2016, 41, 1295-1302.	0.9	15
189	Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1253-1264.	1.9	23
191	Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. <i>Obesity Reviews</i> , 2016, 17, 68-80.	3.1	50
192	Di(2-ethylhexyl) phthalate exacerbates non-alcoholic fatty liver in rats and its potential mechanisms. <i>Environmental Toxicology and Pharmacology</i> , 2016, 42, 38-44.	2.0	66
193	Isoorientin Prevents Hyperlipidemia and Liver Injury by Regulating Lipid Metabolism, Antioxidant Capability, and Inflammatory Cytokine Release in High-Fructose-Fed Mice. <i>Journal of Agricultural and Food Chemistry</i> , 2016, 64, 2682-2689.	2.4	62
194	Modulating the expression of genes associated with hepatic lipid metabolism, lipoperoxidation and inflammation by cocoa, cocoa extract and cocoa flavanols related to hepatic steatosis induced by a hypercaloric diet. <i>Food Research International</i> , 2016, 89, 937-945.	2.9	7
195	Adipokines in nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1062-1079.	1.5	250
197	Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. <i>Journal of the American College of Nutrition</i> , 2016, 35, 346-353.	1.1	87
198	The relationship between visfatin, liver inflammation, and acute phase reactants in chronic viral hepatitis B. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 658-662.	1.0	4
199	Red paprika (<i>Capsicum annuum</i> L.) and its main carotenoid capsanthin ameliorate impaired lipid metabolism in the liver and adipose tissue of high-fat diet-induced obese mice. <i>Journal of Functional Foods</i> , 2017, 31, 131-140.	1.6	35
200	Non-alcoholic fatty liver disease and colorectal cancer. <i>Postgraduate Medical Journal</i> , 2017, 93, 153-158.	0.9	19
201	Adipokine Levels Versus Hepatic Histopathology in Bariatric Surgery Patients. <i>Obesity Surgery</i> , 2017, 27, 2151-2158.	1.1	16

#	ARTICLE	IF	CITATIONS
202	Adrenic acid as an inflammation enhancer in non-alcoholic fatty liver disease. Archives of Biochemistry and Biophysics, 2017, 623-624, 64-75.	1.4	29
203	Sphingolipids and Lipoproteins in Health and Metabolic Disorders. Trends in Endocrinology and Metabolism, 2017, 28, 506-518.	3.1	167
204	High serum alanine aminotransferase is associated with the risk of colorectal adenoma in Korean men. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1310-1317.	1.4	7
205	Soluble soybean polysaccharides enhance the protective effects of genistein against hepatic injury in high <scp> </scp>-carnitine-fed mice. Food and Function, 2017, 8, 4364-4373.	2.1	14
206	Circulating IL-8 levels are increased in patients with type 2 diabetes and associated with worse inflammatory and cardiometabolic profile. Acta Diabetologica, 2017, 54, 961-967.	1.2	64
207	Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis. Clinica Chimica Acta, 2017, 473, 89-95.	0.5	38
208	Nonalcoholic Fatty Liver Disease Is Associated with Increased Risk of Reflux Esophagitis. Digestive Diseases and Sciences, 2017, 62, 3605-3613.	1.1	12
209	Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection. Cytokine, 2017, 90, 54-59.	1.4	17
210	Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology, 2017, 65, 65-77.	3.6	134
211	Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials. Nutrition, 2017, 34, 108-117.	1.1	70
212	CD98 siRNA-loaded nanoparticles decrease hepatic steatosis in mice. Digestive and Liver Disease, 2017, 49, 188-196.	0.4	16
214	Macro Components in Dairy and Their Effects on Inflammation Parameters. , 2017, , 287-302.		0
215	Cytokines in Steatohepatitis. , 2017, , 159-168.		0
216	Nonalcoholic fatty liver disease: Diagnostic biomarkers. World Journal of Gastrointestinal Pathophysiology, 2017, 8, 11.	0.5	101
217	Reduced SHARPIN and LUBAC Formation May Contribute to CCl4- or Acetaminophen-Induced Liver Cirrhosis in Mice. International Journal of Molecular Sciences, 2017, 18, 326.	1.8	8
218	Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. International Journal of Molecular Sciences, 2017, 18, 1649.	1.8	170
219	Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2017, 23, 8263-8276.	1.4	514
220	Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis. Journal of Clinical & Cellular Immunology, 2017, 8, .	1.5	12

#	ARTICLE	IF	CITATIONS
221	Valoración de la enfermedad por hígado graso no alcohólico desde el laboratorio clínico. Revista Del Laboratorio Clínico, 2018, 11, 163-173.	0.1	1
222	Blood-based novel biomarkers for nonalcoholic steatohepatitis. Biomarkers in Medicine, 2018, 12, 501-515.	0.6	2
223	Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity. Obesity Research and Clinical Practice, 2018, 12, 1-8.	0.8	46
224	New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Protein and Cell, 2018, 9, 164-177.	4.8	92
225	Response to kawada: Sleep habits and non-alcoholic fatty liver disease: Risk assessment by adjusting confounders. Journal of Diabetes, 2018, 10, 342-343.	0.8	0
226	Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clinics in Liver Disease, 2018, 22, 73-92.	1.0	73
227	Stable Isotope-Labeled Lipidomics to Unravel the Heterogeneous Development Lipotoxicity. Molecules, 2018, 23, 2862.	1.7	10
228	Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2018, 2, 1344-1355.	2.0	58
229	CORRELATION BETWEEN NONALCOHOLIC FATTY LIVER DISEASE FEATURES AND LEVELS OF ADIPOKINES AND INFLAMMATORY CYTOKINES AMONG MORBIDLY OBESE INDIVIDUALS. Arquivos De Gastroenterologia, 2018, 55, 247-251.	0.3	26
230	Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis. Clinical Interventions in Aging, 2018, Volume 13, 1879-1891.	1.3	37
231	Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 461-478.	8.2	400
232	Chemokines and Chemokine Receptors in the Development of NAFLD. Advances in Experimental Medicine and Biology, 2018, 1061, 45-53.	0.8	68
233	Circulating Serum Level of Visfatin in Patients with Endometrial Cancer. BioMed Research International, 2018, 2018, 1-9.	0.9	24
234	Association between circulating visfatin and gestational diabetes mellitus: a systematic review and meta-analysis. Acta Diabetologica, 2018, 55, 1113-1120.	1.2	14
235	Adiponectin Signaling Pathways in Liver Diseases. Biomedicines, 2018, 6, 52.	1.4	55
236	Sphingolipid metabolism in non-alcoholic fatty liver diseases. Biochimie, 2019, 159, 9-22.	1.3	54
237	Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Cells, 2019, 8, 845.	1.8	92
238	Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis. PLoS ONE, 2019, 14, e0217263.	1.1	15

#	ARTICLE	IF	CITATIONS
239	Effect of dietary intervention, with or without co-interventions, on inflammatory markers in patients with nonalcoholic fatty liver disease: a systematic literature review. <i>Nutrition Reviews</i> , 2019, 77, 765-786.	2.6	11
240	TNF- α in Combination with Palmitate Enhances IL-8 Production via The MyD88- Independent TLR4 Signaling Pathway: Potential Relevance to Metabolic Inflammation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4112.	1.8	32
241	Oral α -lipoic acid supplementation in patients with non-alcoholic fatty liver disease: effects on adipokines and liver histology features. <i>Food and Function</i> , 2019, 10, 4941-4952.	2.1	20
242	Soybean soluble polysaccharides enhance bioavailability of genistein and its prevention against obesity and metabolic syndrome of mice with chronic high fat consumption. <i>Food and Function</i> , 2019, 10, 4153-4165.	2.1	38
243	Association Between Visfatin and Hepatic Steatosis in the General Population During Long-Term Follow-Up. <i>Hormone and Metabolic Research</i> , 2019, 51, 602-607.	0.7	12
244	Association between non-alcoholic fatty liver disease and colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 633-641.	1.4	19
245	The impact of the sleep duration on NAFLD score in Korean middle-aged adults: a community-based cohort study. <i>Sleep Medicine</i> , 2019, 57, 144-150.	0.8	23
246	Emerging Circulating Biomarkers for The Diagnosis and Assessment of Treatment Responses in Patients with Hepatic Fat Accumulation, Nash and Liver Fibrosis. , 2019, , 423-448.		4
247	Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1157-1164.e4.	2.4	62
248	Effects of rilpivirine, 17 β -estradiol and α -naphthoflavone on the inflammatory status of release of adipocytokines in 3T3-L1 adipocytes in vitro. <i>Molecular Biology Reports</i> , 2019, 46, 2643-2655.	1.0	5
249	Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: The ELSA-Brasil. <i>Atherosclerosis</i> , 2019, 284, 59-65.	0.4	15
250	Obesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of Cancer. <i>International Journal of Biological Sciences</i> , 2019, 15, 610-616.	2.6	110
251	Impact of Glucoraphanin-Mediated Activation of Nrf2 on Non-Alcoholic Fatty Liver Disease with a Focus on Mitochondrial Dysfunction. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5920.	1.8	31
252	Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 577-610.	1.4	22
253	The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 258-267.	0.7	25
254	Low serum adiponectin is a predictor of progressing to nonalcoholic fatty liver disease. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22709.	0.9	25
255	Resistin: A reappraisal. <i>Mechanisms of Ageing and Development</i> , 2019, 178, 46-63.	2.2	123
256	Effects of palmitate and astaxanthin on cell viability and proinflammatory characteristics of mesenchymal stem cells. <i>International Immunopharmacology</i> , 2019, 68, 164-170.	1.7	22

#	ARTICLE	IF	CITATIONS
257	Association of Circulating Adipsin, Visfatin, and Adiponectin with Nonalcoholic Fatty Liver Disease in Adults: A Case-Control Study. <i>Annals of Nutrition and Metabolism</i> , 2019, 74, 44-52.	1.0	29
258	Adipose may actively delay progression of NAFLD by releasing tumor-suppressing, anti-fibrotic miR-122 into circulation. <i>Obesity Reviews</i> , 2019, 20, 108-118.	3.1	35
259	Organokines in disease. <i>Advances in Clinical Chemistry</i> , 2020, 94, 261-321.	1.8	24
260	The Hepatoprotective Effects of Zinc Glycine on Liver Injury in Meat Duck Through Alleviating Hepatic Lipid Deposition and Inflammation. <i>Biological Trace Element Research</i> , 2020, 195, 569-578.	1.9	9
261	How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 45-62.	1.0	5
262	A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. <i>Microorganisms</i> , 2020, 8, 1526.	1.6	8
263	Reduced Biliverdin Reductase-A Expression in Visceral Adipose Tissue is Associated with Adipocyte Dysfunction and NAFLD in Human Obesity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9091.	1.8	13
264	Osteocalcin and osteoprotegerin levels and their relationship with adipokines and proinflammatory cytokines in children with nonalcoholic fatty liver disease. <i>Cytokine</i> , 2020, 135, 155215.	1.4	13
265	Chinese Medicinal Herbs Targeting the Gut-Liver Axis and Adipose Tissue-Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science. <i>Frontiers in Endocrinology</i> , 2020, 11, 572729.	1.5	15
266	Fermented mulberry (<i>Morus alba</i>) leaves suppress high fat diet-induced hepatic steatosis through amelioration of the inflammatory response and autophagy pathway. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 283.	1.2	18
267	Omeprazole and <i>Spirulina Platensis</i> Ameliorate Steatohepatitis in Experimental Nonalcoholic Fatty Liver Disease. <i>Metabolic Syndrome and Related Disorders</i> , 2020, 18, 426-434.	0.5	6
268	The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests. <i>American Journal of Surgery</i> , 2021, 222, 214-219.	0.9	9
269	Pathobiological and molecular connections involved in the high fructose and high fat diet induced diabetes associated nonalcoholic fatty liver disease. <i>Inflammation Research</i> , 2020, 69, 851-867.	1.6	7
270	Hepatic consequences of COVID-19 infection. Lapping or biting?. <i>European Journal of Internal Medicine</i> , 2020, 77, 18-24.	1.0	86
271	Combination of asprosin and adiponectin as a novel marker for diagnosing non-alcoholic fatty liver disease. <i>Cytokine</i> , 2020, 134, 155184.	1.4	22
272	Relationship between IL-8 Circulating Levels and TLR2 Hepatic Expression in Women with Morbid Obesity and Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4189.	1.8	26
273	COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13338.	1.7	104
274	Non-alcoholic fatty liver disease among patients with sleep disorders: a Nationwide study of Taiwan. <i>BMC Gastroenterology</i> , 2020, 20, 32.	0.8	11

#	ARTICLE	IF	CITATIONS
275	Alpha-lipoic acid effect on leptin and adiponectin concentrations: a systematic review and meta-analysis of randomized controlled trials. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 649-657.	0.8	8
276	Commentary: non-alcoholic steatohepatitis" finding and minding the fire behind the smoke. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 209-211.	1.9	0
277	Site-specific risk of colorectal neoplasms in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0245921.	1.1	11
278	Fibrosis and hepatic regeneration mechanism. <i>Translational Gastroenterology and Hepatology</i> , 2022, 7, 9-9.	1.5	8
279	TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism. <i>Frontiers in Endocrinology</i> , 2020, 11, 613639.	1.5	21
280	Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2020, 11, 634409.	2.2	18
281	TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation. <i>Frontiers in Immunology</i> , 2020, 11, 609060.	2.2	47
282	Caspase-Cleaved Keratin 18 Measurements Identified Ongoing Liver Injury after Bariatric Surgery. <i>Journal of Clinical Medicine</i> , 2021, 10, 1233.	1.0	8
283	Relationships between plasma levels and six proinflammatory interleukins and body composition using a new magnetic resonance imaging voxel-based technique. <i>Cytokine: X</i> , 2021, 3, 100050.	0.5	5
284	Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 663351.	1.5	10
285	Regulation and functional roles of chemokines in liver diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 630-647.	8.2	46
286	Serum Resistin Levels in Adult Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	7
287	Porphyran-derived oligosaccharides alleviate NAFLD and related cecal microbiota dysbiosis in mice. <i>FASEB Journal</i> , 2021, 35, e21458.	0.2	12
288	A review on molecular mechanism of alcoholic liver disease. <i>Life Sciences</i> , 2021, 274, 119328.	2.0	31
289	Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3029.	1.0	15
290	Circulating tumor necrosis factor α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3002-3014.	1.4	30
291	Lupinus angustifolius Protein Hydrolysates Reduce Abdominal Adiposity and Ameliorate Metabolic Associated Fatty Liver Disease (MAFLD) in Western Diet Fed-ApoE $^{-/-}$ Mice. <i>Antioxidants</i> , 2021, 10, 1222.	2.2	16
292	Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression. <i>Frontiers in Immunology</i> , 2021, 12, 708959.	2.2	37

#	ARTICLE	IF	CITATIONS
293	Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 171-189.	1.4	2
294	Decoding the Pathophysiology of Non-alcoholic Fatty Liver Disease Progressing to Non-alcoholic Steatohepatitis: A Systematic Review. <i>Cureus</i> , 2021, 13, e18201.	0.2	7
295	Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications. <i>Methods in Molecular Biology</i> , 2022, 2343, 19-35.	0.4	4
296	Fatty Liver Disease. , 2010, , 201-222.		1
297	Pathogenesis of Nonalcoholic Fatty Liver Disease. , 2018, , 369-390.e14.		2
298	Strong association between serum Vitamin D and Vaspin Levels, AIP, VAI and liver enzymes in NAFLD patients. <i>International Journal for Vitamin and Nutrition Research</i> , 2020, 90, 59-66.	0.6	17
299	Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1.	0.8	51
300	Circulating Level of CTRP1 in Patients with Nonalcoholic Fatty Liver Disease (NAFLD): Is It through Insulin Resistance?. <i>PLoS ONE</i> , 2015, 10, e0118650.	1.1	28
301	Associations of circulating chemerin and adiponectin concentrations with hepatic steatosis. <i>Endocrine Connections</i> , 2019, 8, 1097-1107.	0.8	8
302	Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets. <i>Oncotarget</i> , 2017, 8, 60673-60683.	0.8	14
303	Serum Bilirubin Correlates with Serum Adipokines in Normal Weight and Overweight Asymptomatic Adults. <i>Acta Clinica Croatica</i> , 2020, 59, 19-29.	0.1	6
304	Ancient wheats: beneficial effects on insulin resistance. <i>Minerva Medica</i> , 2021, 112, 641-650.	0.3	20
305	Hepatocyte steatosis increases the expression of adhesion molecules in endothelial cells. <i>Asian Biomedicine</i> , 2010, 4, 757-763.	0.2	3
306	Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 279.	4.5	13
307	What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2013, 19, 802.	1.4	164
308	Pro-atherosclerotic markers and cardiovascular risk factors one year after liver transplantation. <i>World Journal of Gastroenterology</i> , 2014, 20, 8667.	1.4	13
309	Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. <i>World Journal of Gastroenterology</i> , 2014, 20, 10851.	1.4	93
310	Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. <i>World Journal of Gastroenterology</i> , 2014, 20, 12082.	1.4	155

#	ARTICLE	IF	CITATIONS
311	Association between nonalcoholic fatty liver disease and colorectal adenoma: a systemic review and meta-analysis. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 440-6.	0.6	29
312	Insomnia and risk of nonalcoholic fatty liver disease. <i>Journal of Postgraduate Medicine</i> , 2017, 63, 226-231.	0.2	18
313	Angiogenesis and liver fibrosis. <i>World Journal of Hepatology</i> , 2015, 7, 377.	0.8	120
314	Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. <i>World Journal of Hepatology</i> , 2015, 7, 1192.	0.8	8
315	ÂVaspin, resistin, retinol-binding protein-4, interleukin-1Î± and interleukin-6 in patients with nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2016, 15, 705-14.	0.6	24
316	Basil Essential Oil and Its Nanoemulsion Mitigate Non Alcoholic Steatohepatitis in Rat Model with Special Reference to Gut Microbiota. <i>Journal of Oleo Science</i> , 2020, 69, 913-927.	0.6	5
317	Interpretation of Serum Visfatin Level in Relation to Hepatic Injury is Probably Gender Dependent in Nonalcoholic Fatty Liver Disease. <i>Hepatitis Monthly</i> , 2017, 17, .	0.1	1
318	Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran. <i>Hepatitis Monthly</i> , 2015, 15, e32418.	0.1	5
319	Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran. <i>Hepatitis Monthly</i> , 2015, 15, e33462.	0.1	6
320	Association between Inflammatory Biomarkers and Nutritional Status in Fatty Liver. <i>Clinical Nutrition Research</i> , 2020, 9, 182.	0.5	7
321	The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease. <i>Biomedicines</i> , 2021, 9, 1401.	1.4	13
322	Identification of Serum Biomarkers in End Stage Liver Disease. <i>Open Biomarkers Journal</i> , 2010, 3, 1-6.	0.1	4
324	Metabolic Aspects of Hepatitis C Virus Infection. , 0, , .		0
325	Liver regeneration in nonalcoholic fatty liver disease. <i>Medwave</i> , 2012, 12, e5559-e5559.	0.2	1
326	Nutritional and Metabolic Profile in Nonalcoholic Fatty Liver Disease after Lifestyle Management. <i>Journal of Scientific Research and Reports</i> , 2015, 5, 468-478.	0.2	0
327	Role of adipokines in the pathogenesis of nonalcoholic fatty liver disease. <i>The Journal of Clinical and Scientific Research</i> , 2015, 4, 31.	0.1	1
329	Role of Endotoxin and TNF in Developing NAFLD in Non-Obese Egyptian Patients. <i>Journal of Biosciences and Medicines</i> , 2017, 05, 7-15.	0.1	0
330	EVALUATION OF CONTENT OF CITOKINS IN PATIENTS; 1/2 BLOOD WITH NON-ALCOHOLIC STEATOHEPATITIS COMBINED WITH DIABETES MELLITUS TYPE 2 UNDER THE INFLUENCE OF COMBINED SUCTIONAL THERAPY. <i>Bulletin of Problems Biology and Medicine</i> , 2018, 1.2, 170.	0.0	1

#	ARTICLE	IF	CITATIONS
331	Study of serum visfatin level in patients with nonalcoholic fatty liver disease and its role in progression to nonalcoholic steatohepatitis. <i>Egyptian Liver Journal</i> , 2018, 8, 49-54.	0.3	0
332	The Association between Interleukin-6 and Mean Platelet Volume Levels in Central Obesity with or without Non-Alcoholic Fatty Liver Disease. <i>The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy</i> , 2020, 21, 193-198.	0.0	0
333	Association of pro-inflammatory cytokines, adipokines & oxidative stress with insulin resistance & non-alcoholic fatty liver disease. <i>Indian Journal of Medical Research</i> , 2012, 136, 229-36.	0.4	37
334	Polycystic ovary syndrome and nonalcoholic fatty liver disease. , 2022, , 187-216.		1
336	Severity of inflammatory syndrome and endothelial dysfunction in steatosis and liver fibrosis. <i>Perm Medical Journal</i> , 2021, 38, 54-61.	0.0	2
337	Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. <i>Diagnostics</i> , 2022, 12, 407.	1.3	22
338	Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. <i>Psoriasis: Targets and Therapy</i> , 2021, Volume 11, 151-168.	1.2	10
339	Fibromax and inflamatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease. <i>Minerva Gastroenterology</i> , 2022, 68, .	0.3	5
340	The promising role of CCL2 as a noninvasive marker for nonalcoholic steatohepatitis diagnosis in Egyptian populations. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e954-e960.	0.8	3
342	Receptor-interacting protein kinase-1 ablation in liver parenchymal cells promotes liver fibrosis in murine NASH without affecting other symptoms. <i>Journal of Molecular Medicine</i> , 2022, , 1.	1.7	2
344	Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep's Clothing?. <i>Current Oncology</i> , 2022, 29, 4478-4510.	0.9	6
345	Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?. <i>Biology</i> , 2022, 11, 1237.	1.3	23
346	The biological clock enhancer nobiletin ameliorates steatosis in genetically obese mice by restoring aberrant hepatic circadian rhythm. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 323, G387-G400.	1.6	9
347	Evaluation of Serum Omentin-1, Vaspin, Leptin, Adiponectin Levels in Obese/Overweight Children and Their Relationship With Non-Alcoholic Fatty Liver Disease. <i>Clinical Nutrition Research</i> , 2022, 11, 194.	0.5	4
348	Increased Secreted Frizzled-Related Protein 5 mRNA Expression in the Adipose Tissue of Women with Nonalcoholic Fatty Liver Disease Associated with Obesity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9871.	1.8	1
349	Dietary EPA+DHA Mitigate Hepatic Toxicity and Modify the Oxylipin Profile in an Animal Model of Colorectal Cancer Treated with Chemotherapy. <i>Cancers</i> , 2022, 14, 5703.	1.7	0
350	Overview of Cellular and Soluble Mediators in Systemic Inflammation Associated with Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2313.	1.8	7
351	The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease. <i>Life</i> , 2023, 13, 419.	1.1	8

#	ARTICLE	IF	CITATIONS
352	Stat3 role in the protective effect of FXR Agonist in parenteral nutrition-associated cholestasis. Hepatology Communications, 2023, 7, .	2.0	1
353	Concurrent HCV or fatty liver in patients with chronic hepatitis B virus infection. , 2023, , 581-599.		0
354	Gut Microbiota: A Future Clinical Magic Bullet to Manifest Pathogenic Disease in the Current Future. Journal of Pure and Applied Microbiology, 2023, 17, 51-68.	0.3	0
355	Association between caffeine intake and liver biomarkers in non-alcoholic fatty liver disease. Cukurova Medical Journal, 2023, 48, 177-186.	0.1	0
356	Clinical Spectrum and Trajectory of Innovative Therapeutic Interventions for Insomnia: A Perspective. , 2022, .		1
360	Mean platelet volume for differentiating non-alcoholic fatty liver disease from non-alcoholic steatohepatitis: Is it ready for prime time?. Indian Journal of Gastroenterology, 2023, 42, 156-157.	0.7	0